USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: VIRRX, INC
City: CHESTERFIELD
State: MO
Zip+4: 63017
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $649,265.00 3
STTR Phase I $836,159.00 6
STTR Phase II $711,039.00 1

Award List:

ADENOVIRUS REPLICATION-COMPETENT ANTI-CANCER VECTOR

Award Year / Program / Phase: 2002 / STTR / Phase I
Agency: HHS
Research Institution: ST. LOUIS UNIV. SCHOOL OF MEDICINE
Principal Investigator: William S. Wold
Award Amount: $0.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): We have developed several tumor-specific and tissue-specific replication-competent adenoviruses (Ad) vectors for cancer gene therapy. One vector, named KD3, has a mutation in the E1A gene such that KD3 cannot replicate in, and destroy, "normal" cells. However,… More

DEVELOPMENT OF A VIRUS VECTOR VACCINE AGAINST ANTHRAX

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Peter Krajcsi
Award Amount: $140,710.00
Abstract:
DESCRIPTION (provided by applicant): The events on and following September 11, 2001 have revealed our nation's vulnerability to terrorist attacks. Although much talked about during the past decade, the threat of a bioterrorist attack against the United States was not realized until the intentional… More

Chaperone-based tumor therapy delivered by viral vectors

Award Year / Program / Phase: 2003 / STTR / Phase I
Agency: HHS
Research Institution: ST. LOUIS UNIVERSITY
Principal Investigator: Michael H. Green
Award Amount: $169,167.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): The efficacy of molecular chaperones as adjuvants for the induction of anti-tumor immunity has been demonstrated in many laboratories over the last two decades. Similarly, the exploration of the therapeutic use of poxviruses in cancer treatment has a long and… More

Animal Model for Adenovirus Oncolytic Vectors

Award Year / Program / Phase: 2004 / STTR / Phase I
Agency: HHS
Research Institution: ST. LOUIS UNIVERSITY
Principal Investigator: William S. Wold
Award Amount: $182,459.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Adenovirus vectors have also been evaluated for their efficacy in treating cancer. As cancer is the second leading cause of death in the U.S. and current therapeutics are not always sufficient, new cancer therapies are desired. Replication-competent oncolytic… More

Anti-Cancer Vectors that Express TRAIL

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Drew L. Lichtenstein
Award Amount: $247,645.00
Abstract:
DESCRIPTION (provided by applicant): We have developed replication-competent oncolytic adenovirus (Ad) vectors for cancer gene therapy that are designed to spread rapidly from cell to cell by virtue of the fact that they express ADP, an Ad protein that is expressed predominantly late in… More

Regulatable expression of TRAIL and viral oncolysis

Award Year / Program / Phase: 2004 / STTR / Phase I
Agency: HHS
Research Institution: ST. LOUIS UNIVERSITY
Principal Investigator: Konstantin Doronin
Award Amount: $161,875.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): We have constructed an oncolytic adenovirus vector named "KD3" that replicates selectively in cancer cells as opposed to normal cells because of a mutation in the adenovirus E1A gene that prevents E1A proteins from deregulating the cell cycle in normal cells.… More

Syrian Hamster as a Permissive Model for Testing Anti-Adenovirus Drugs

Award Year / Program / Phase: 2007 / STTR / Phase I
Agency: HHS
Research Institution: SAINT LOUIS UNIVERSITY
Principal Investigator: William S. Wold
Award Amount: $222,658.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Human adenoviruses (Ads) are a significant problem in immunosuppressed humans, especially in children undergoing allogeneic stem cell transplants. About 20% of these pediatric patients develop disseminated Ad infections and about half of the patients die. There… More

An HBV polymerase RNA binding assay suitable for inhibitor screening

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Feng Cao
Award Amount: $260,910.00
Abstract:
DESCRIPTION (provided by applicant): Hepatitis B virus (HBV) is a hepatotropic DNA virus that replicates by reverse transcription. It chronically infects over 350 million people worldwide and causes 600,000 deaths annually. Current therapies for HBV infect ion use interferon 1 or one of five… More